



2024 SEMI-ANNUAL REPORT

**MIDDLEFIELD
HEALTHCARE**
DIVIDEND ETF

 **MIDDLEFIELD**
ETFs



MIDDLEFIELD CORPORATE PROFILE

The Middlefield Group was established in 1979 and is a Specialty Investment Manager which creates investment products designed to balance risk and return to meet the demanding requirements of Financial Advisors and their clients. These financial products include Exchange-Traded Funds, Mutual Funds, Private and Public Resource Funds, Split Share Corporations, Venture Capital Assets, TSX Publicly Traded Funds and Real Estate Investment Funds and Partnerships.

Middlefield's investment team comprises portfolio managers, analysts and traders. While all of our investment products are designed and managed by Middlefield professionals, some involve strategic partnerships with other "best-in-class" firms that bring unique value to our product offerings. In 2014, we entered into an exclusive arrangement with SSR, LLC, based in Stamford, Connecticut. They provide specialized research into sectors of the economy such as Healthcare and Innovation Technology. SSR is an independent investment firm whose analysts have been highly ranked and are recognized as leaders in their respective fields. Their fundamental company level research is often non-consensus and provides guidance on overall portfolio construction and security selection.

Looking ahead, Middlefield remains committed to managing and developing new and unique investment products to assist Financial Advisors in helping clients achieve their investment objectives.

TABLE OF CONTENTS

	Corporate Profile
	2024 Mid-Year Review and Outlook
4	Interim Management Report of Fund Performance
11	Interim Financial Report
16	Notes to Financial Statements Middlefield Funds Family

A NOTE ON FORWARD LOOKING STATEMENTS

This document may contain forward looking statements, including statements regarding: the Fund, its strategies, goals and objectives; prospects; future performance or condition; possible future actions to be taken by the Fund; and the performance of investments, securities, issuers or industries in which the Fund may from time to time invest. Forward looking statements include statements that are predictive in nature, that depend upon or refer to future results, events, circumstances, expectations and performance, or that include words such as "expects", "anticipates", "intends", "plans", "believes", "estimates" or negative versions thereof and other similar wording. Forward looking statements are not historical facts, but reflect the Fund's current beliefs as of the date of this document regarding future results, events, circumstances, expectations or performance and are inherently subject to, among other things, risks, uncertainties and assumptions about the Fund and economic factors. Forward looking statements are not guarantees of future performance, and actual results, events, circumstances, expectations or performance could differ materially from those expressed or implied in any forward looking statements contained in this document. Factors which could cause actual results, events, circumstances, expectations or performance to differ materially from those expressed or implied in forward looking statements include, but are not limited to: general economic, political, market and business factors and conditions; commodity price fluctuations; interest and foreign exchange rate fluctuations; global equity and capital markets; the financial condition of each issuer in which the Fund invests; the effects of competition in the industries or geographic areas in which the Fund may invest; statutory and regulatory developments; unexpected judicial or regulatory proceedings; and catastrophic events. Readers are cautioned that the foregoing list of factors is not exhaustive and to avoid placing undue reliance on forward looking statements due to the inherent uncertainty of such statements. The Fund does not undertake, and specifically disclaims, any obligation to update or revise any forward looking statements, whether as a result of new information, future developments, or otherwise.



2024 MID-YEAR REVIEW AND OUTLOOK

The S&P 500 generated a total return of 15.3% in the first half of 2024, reaching 33 new all-time highs along the way. The year-to-date return breaks down into 7.1% from improved earnings expectations, 7.4% from expansion in the forward P/E multiple to 21x, and 0.8% from dividends. Sectors linked to the AI thematic led to the upside with Information Technology and Communication Services returning 28% and 27%, respectively. Index heavyweights Microsoft, Nvidia, Apple, Google, Amazon, and Meta contributed to 62% of the index's total return.

YTD S&P 500 Return Attribution			
Sector	Weight at Start of 2024 (%)	YTD Return (%)	Contribution of S&P 500 Return (basis points)
Info Tech	29	28	815
Comm. Services	9	27	229
Financials	13	10	132
Health Care	13	8	98
Industrials	9	8	68
Cons. Discretionary	11	6	61
Cons. Staples	6	9	55
Energy	4	11	42
Utilities	2	9	22
Materials	2	4	10
Real Estate	2	-2	-5
S&P 500	100	15	1529

Source: FactSet, Goldman Sachs Global Investment Research

The TSX Composite Index generated a total return of 6.1% in H1, lagging the U.S. market by nearly 10%. Half of the performance gap occurred in June when the TSX returned -1.4% compared to 3.6% for the S&P 500. Canada's three largest sectors - Energy, Materials and Financials - all had negative returns in June which explains most of the underperformance. With the Bank of Canada (BoC) entering an easing cycle on June 5th, we expect relative performance of Canadian equities to rebound. Historically, the TSX has averaged double-digit gains 12 months after the first BoC rate cut. We believe core defensive yield sectors including utilities and real estate are particularly well-positioned to outperform in the second half.

A common theme that emerged during the second quarter was normalization. Growth expectations, inflation and employment stats have all been easing from abnormally high levels recently. We view this trend positively as long as the pace of easing remains gradual and these key economic data return to more normalized levels. We do not forecast a recession in the U.S. or Canada over the next twelve months and believe the evolving macro landscape is conducive to continued strong performance from North American equity markets.

Middlefield Real Estate Dividend ETF (TSX:MREL) outperformed its benchmark in H1, outperforming the S&P/TSX Capped REIT Total Return by 4.2%. Canadian REITs returned 0.6% in June, outperforming the TSX Composite by 2%. The BoC's decision to cut rates on June 5th is showing early signs of improving sentiment for the sector. There are four BoC meetings remaining in 2024 and the Overnight Index Swaps market is currently pricing nearly two more full cuts from the BoC before year-end.

Canada's population has increased 8% since pre-pandemic levels. Supply of real estate has not kept pace with the surge in demand, causing Canada's per capita housing stock and shopping centre space to fall by 2% and 6%, respectively. As a result, vacancy rates have fallen to historic lows within these asset classes and rents have gone up. Apartment rents have risen close to 10% year-over-year while retail property leasing spreads are also in the high single-digits. The operating environment is as attractive as it has ever been for these asset classes and when investor focus finally shifts from interest rates to fundamentals, we expect a swift re-rating in REIT unit prices.

Middlefield Innovation Dividend ETF (TSX:MINN) generated a total return of 33.6% in H1 2024, exceeding the NASDAQ Technology Dividend TR Index return by 10.1%. The outperformance was primarily influenced by the fund's overweighting in growth-oriented technology securities. The first half of 2024 witnessed a clear divergence in the tech landscape: Artificial Intelligence (AI) stocks skyrocketed 33.3%, while non-profitable tech stocks suffered an 18.7% decline. This trend underscored the growing dominance of AI, a theme we anticipate will continue to shape the market. Our investment approach aligns with this shifting paradigm. We remain steadfast in our conviction that AI-focused semiconductor companies are poised for sustained growth, given their pivotal role in fueling the AI revolution.

MIDDLEFIELD TSX-LISTED FUNDS |

The Middlefield Family of exchange-listed funds is currently comprised of 13 funds, 12 of which trade on the Toronto Stock Exchange and one of which is based in Jersey, Channel Islands and trades on the London Stock Exchange. The fund mandates differ by asset mix including both Canadian and International equity securities.

Middlefield Sustainable Infrastructure Dividend ETF (TSX:MINF) returned 6.9% in the first six months of 2024. Infrastructure presents a compelling long-term investment opportunity due to its defensive characteristics, while offering high dividend yields and inflation protection. Several key themes are driving growth in the sector, including accelerating data center demand, energy security, and the upgrading of existing infrastructure. Our **Infrastructure Dividend Split Corp. (TSX: IS)** capitalizes on these trends and specifically invests in dividend-paying securities across various sectors within the infrastructure asset class, including Utilities, Energy, Real Estate and Industrials. The current macro environment is supportive of global infrastructure spending due to a constructive earnings outlook, improving CapEx cycle, increased fiscal focus on infrastructure, and a falling interest rate environment. Historically, infrastructure assets have performed well in periods of “Above Trend and Falling” rate environments. The Bank of Canada’s recent 25 bp rate cut marks the start of an easing monetary policy, which will be a significant tailwind for the sector.

Middlefield Sustainable Global Dividend ETF (TSX:MDIV) and Middlefield U.S. Equity Dividend ETF (TSX:MUSA) generated returns of 23.6% and 25.1% respectively, outperforming their benchmarks (MSCI World Dividend Growers Quality 8.0% and S&P 500 Dividend Aristocrats 5.9%) by upper teens to low twenties. The anticipated Fed easing cycle in H2 of 2024 should ultimately serve as a tailwind for equities, with dividend-paying stocks particularly well-positioned to outperform in a falling rate environment.

Middlefield Healthcare Dividend ETF (TSX:MHCD) generated a total return of 13.5% in H1 2024, exceeding its benchmark. Healthcare had a strong first half of 2024 with the MSCI World Healthcare Index returning 8.2%. Like the broader market, the sector’s performance was driven by a concentrated group of companies, many of which contributed to the outperformance of our healthcare funds in H1. On the topic of R&D, we are witnessing a sea change in how companies are approaching early-stage clinical research. AI has the potential to revolutionize R&D efforts by improving drug discovery timeline and accuracy. Machine learning algorithms can predict how potential drug candidates will interact with targets in the body before they are tested in the clinic. These capabilities will allow researchers to pursue only the most promising drug candidates in the clinic and avoid much of the trial-and-error that goes into research today.

Outlook

Although the Federal Reserve has maintained its hawkish stance in recent press conferences, the normalization of economic data we are witnessing supports an easing cycle in the U.S. as well. As of early July, Fed Funds Futures are implying an 80% chance that the Fed will cut rates at its September meeting. With the Fed now having less to worry about on both sides of its dual mandate, we agree that a rate cut in September would be an appropriate course of action. Given the impressive run the market has been on so far this year, we would not be surprised to see a short-term pullback in major indices during the second half of Q3. Given our positive outlook on the macro landscape, and the projected earnings growth over the next two years, we view any near-term market pullback as a healthy correction within a broader secular bull market and would be buyers of high-quality stocks on weakness.



Dean Orrico
President and CEO
Middlefield Capital Corporation



Robert F. Lauzon
Managing Director and Chief Investment Officer
Middlefield Capital Corporation

INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE SIX MONTHS ENDED JUNE 30, 2024

This interim management report of fund performance contains financial highlights but does not contain the annual financial statements of the investment fund. This report should be read in conjunction with the complete interim financial report of the investment fund that follows this report. The interim financial report has not been reviewed by the investment fund's external auditors.

Unitholders may contact us by calling 1-888-890-1868, by writing to us at Middlefield Group at one of the addresses on the back cover or by visiting our website at www.middlefield.com to request a copy of the investment fund's annual financial statements, proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure.

Management's Discussion of Fund Performance

Investment Objectives and Strategies

The investment objectives of Middlefield Healthcare Dividend ETF (the "Fund") are to provide holders with: (i) stable monthly cash distributions; and (ii) enhanced long-term total return through capital appreciation of the Fund's investment portfolio. The Fund utilizes an investment strategy which focuses primarily on investing in dividend-paying securities of issuers operating in or that derive a significant portion of their earnings or revenue from products or services related to the healthcare, life sciences and related industries.

Results of Operations

Investment Performance

During the first half of 2024, the net assets of the Fund increased to \$160.8 million at June 30, 2024 from \$146.7 million at December 31, 2023. On a per unit basis, the net assets of the Fund increased from \$10.68 at December 31, 2023 to \$11.81 at June 30, 2024. The Fund recorded a net gain on its investment portfolio of approximately \$19.0 million or \$1.38 per unit during the period.

Revenue and Expenses

Revenue before expenses for the period ended June 30, 2024 amounted to \$21.0 million, up from a loss of \$1.2 million in 2023 primarily as a result of unrealized gain on the Fund's portfolio investments. Operating expenses amounted to \$1.1 million in the first half of 2024, up from \$0.7 million in 2023. The operating expenses contributed to the management expense ratio ("MER") of 1.25% in the first six months of 2024, unchanged from the same period in 2023. As a result, profit after tax amounted to \$19.7 million or \$1.43 per unit, increased from a loss of \$2.0 million or \$0.21 per unit in the prior period. Distributions for the six months ended June 30, 2024 amounted to \$0.30 per unit.

Trends

Healthcare had a strong first half of 2024 with the MSCI World Healthcare Index returning 8.2%. We are witnessing a sea change in how companies are approaching early-stage clinical research. AI has the potential to revolutionize R&D efforts by improving drug discovery timeline and accuracy. Machine learning algorithms can predict how potential drug candidates will interact with targets in the body before they are tested in the clinic. These capabilities will allow researchers to pursue only the most promising drug candidates in the clinic and avoid much of the trial-and-error that goes into research today.

Related Party Transactions

Pursuant to a management agreement, Middlefield Limited (the "Manager") receives a management fee. For further details, please see the "Management Fees" section of this report. Middlefield Capital Corporation ("MCC" or the "Advisor"), the advisor to the Fund and a company under common control with the Manager, receives advisory fees from the Manager out of the management fee. MCC also receives brokerage commissions from the Fund in connection with securities transactions. All brokerage commissions paid by the Fund to MCC were at or below market rates. For further details, please see the notes to the financial statements.

Management Fees

Management fees are calculated at 0.85% per annum of the net asset value of the Fund and are split between the Manager and the Advisor. The Manager receives fees for the general administration of the Fund, including maintaining the accounting records, executing securities trades, monitoring compliance with regulatory requirements, and negotiating contractual agreements, among other things. The Advisor receives fees from the Manager for providing investment advice in respect of the portfolio in accordance with the investment objectives and strategies of the Fund.

Financial Highlights

Net Assets are calculated in accordance with International Financial Reporting Standards ("IFRS").

"Net Asset Value" is calculated in accordance with section 14.2 of National Instrument 81-106 "Investment Fund Continuous Disclosure" ("NI 81-106") and is used for transactional pricing purposes.

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the indicated periods. Ratios and Supplemental Data are derived from the Fund's Net Asset Value.

INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE SIX MONTHS ENDED JUNE 30, 2024

The Fund's Net Assets per Unit⁽¹⁾

	June 30, 2024 ⁽⁴⁾	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Net Assets, Beginning of Period	\$ 10.68	\$ 11.34	\$ 12.06	\$ 11.10	\$ 10.61	\$ 9.95
INCREASE (DECREASE) FROM OPERATIONS:						
Total Revenue	0.14	0.21	0.17	0.13	0.16	0.17
Total Expenses (excluding distributions)	(0.09)	(0.17)	(0.16)	(0.17)	(0.16)	(0.16)
Realized Gains (Losses) for the Period	(0.08)	(0.12)	0.41	0.19	0.49	0.27
Unrealized Gains (Losses) for the Period	1.46	0.02	(0.49)	1.37	0.58	1.01
Transaction Costs on Purchase and Sale of Investments	-	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)
TOTAL INCREASE (DECREASE) FROM OPERATIONS⁽²⁾	1.43	(0.06)	(0.12)	1.56	1.09	1.23
DISTRIBUTIONS:						
From Net Investment Income	0.05	0.04	-	-	-	0.01
From Capital Gains	-	-	0.41	0.19	0.48	0.26
Return of Capital	0.25	0.56	0.19	0.41	0.12	0.30
TOTAL DISTRIBUTIONS⁽³⁾	0.30	0.60	0.60	0.60	0.60	0.57
Net Assets, End of Period	\$ 11.81	\$ 10.68	\$ 11.34	\$ 12.06	\$ 11.10	\$ 10.61

⁽¹⁾ This information is derived from the Fund's audited annual financial statements and unaudited interim financial report.

⁽²⁾ Net Assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the financial period. This schedule is not a reconciliation of Net Assets since it does not reflect unitholder transactions as shown on the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units and accordingly columns may not add.

⁽³⁾ Distributions were paid in cash/reinvested in additional units of the Fund, or both.

⁽⁴⁾ For the six-month period ended June 30, 2024.

INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE SIX MONTHS ENDED JUNE 30, 2024

Ratios and Supplemental Data

	June 30, 2024 ⁽⁴⁾	December 31, 2023	December 31, 2022	December 31, 2021	December 31, 2020	December 31, 2019
Total Assets (000s)	\$ 161,542	\$ 147,705	\$ 89,078	\$ 88,747	\$ 76,183	\$ 79,456
Total Net Asset Value (000s)	\$ 160,778	\$ 146,733	\$ 88,626	\$ 88,245	\$ 75,705	\$ 78,968
Number of Units Outstanding	13,612,199	13,737,199	7,818,521	7,318,521	6,818,521	7,443,521
Management Expense Ratio ("MER") ⁽¹⁾	1.25%	1.34%	1.27%	1.33%	1.31%	1.41%
MER (excluding interest expense and issuance costs) ⁽¹⁾	1.25%	1.34%	1.27%	1.33%	1.31%	1.40%
Trading Expense Ratio ⁽²⁾	0.09%	0.08%	0.06%	0.05%	0.14%	0.14%
Portfolio Turnover Rate ⁽³⁾	17.60%	32.98%	31.21%	25.49%	59.84%	54.40%
Net Asset Value per Unit	\$ 11.81	\$ 10.68	\$ 11.34	\$ 12.06	\$ 11.10	\$ 10.61

⁽¹⁾ The MER is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average Net Asset Value during the period. The MER excluding interest expense and issuance costs has been presented separately as it expresses only the ongoing management and administrative expenses of the Fund as a percentage of average Net Asset Value. Issuance costs are one-time costs incurred at inception, and the inclusion of interest expense does not consider the additional revenues that have been generated from the investment of the leverage in income-generating assets.

⁽²⁾ The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average Net Asset Value during the period.

⁽³⁾ The Fund's portfolio turnover rate indicates how actively the Fund's portfolio investments are managed. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the period. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

⁽⁴⁾ As at June 30, 2024 or for the six-month period ended June 30, 2024, as applicable.

INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE


FOR THE SIX MONTHS ENDED JUNE 30, 2024

Past Performance

The performance information shown, which is based on Net Asset Value, assumes that all distributions paid by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

Year-By-Year Returns

The bar chart shows how the Fund's performance has varied from year to year for each of the years shown. The return for 2017 is not presented since it relates to a partial period. The chart indicates, in percentage terms, how much an investment made the first day of the financial period would have grown or decreased by the last day of the financial period.



*For the six-month period ended June 30, 2024.

INTERIM MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE SIX MONTHS ENDED JUNE 30, 2024

Summary of Investment Portfolio

AS AT JUNE 30, 2024

Top Twenty-Five Holdings

DESCRIPTION	% OF NET ASSET VALUE
1 Eli Lilly & Company	8.0
2 AstraZeneca PLC	5.7
3 Merck & Co., Inc.	5.3
4 UnitedHealth Group Inc.	5.2
5 Abbvie Inc.	5.1
6 Chartwell Retirement Residences	4.6
7 Boston Scientific Corp.	4.5
8 Novo Nordisk A/S	4.2
9 Thermo Fisher Scientific Inc.	4.0
10 Stryker Corp.	3.9
11 Johnson & Johnson	3.9
12 McKesson Corp.	3.2
13 Intuitive Surgical Inc.	3.0
14 Elevance Health Inc.	2.9
15 Amgen Inc.	2.7
16 Sanofi S.A.	2.6
17 Danaher Corp.	2.4
18 DexCom, Inc.	2.4
19 Vertex Pharmaceuticals Inc.	2.4
20 Abbott Laboratories	2.4
21 Gilead Sciences Inc.	2.3
22 Medtronic PLC	2.0
23 Novartis AG	1.8
24 GSK PLC	1.8
25 Ventas Inc.	1.7

"Top Twenty-Five Holdings" excludes any temporary cash investments.

ASSET CLASS	% OF NET ASSET VALUE
Healthcare	91.5
Real Estate	7.8
Cash and Short-Term Investments	1.0
Other Assets (Liabilities)	(0.3)
	100.0

TOTAL NET ASSET VALUE \$ 160,777,807

TOTAL ASSETS \$ 161,541,528

The Summary of Investment Portfolio may change over time due to ongoing portfolio transactions. Please visit www.middlefield.com for the most recent quarter-end Summary of Investment Portfolio.

**FINANCIAL
STATEMENTS**





INTERIM FINANCIAL REPORT

NOTICE

The accompanying unaudited financial statements of Middlefield Healthcare Dividend ETF for the period ended June 30, 2024 have been prepared by management and have not been reviewed by the external auditors of the Fund.



Jeremy Brasseur
Director
Middlefield Limited



Craig Rogers
Director
Middlefield Limited

August 23, 2024

INTERIM FINANCIAL REPORT

UNAUDITED

Statements of Financial Position

AS AT

(In Canadian Dollars)

June 30, 2024

December 31, 2023

ASSETS

Current Assets

Investments at Fair Value through Profit or Loss	\$	159,714,723	\$	144,888,518
Cash		1,648,315		2,519,020
Income and Interest Receivable		178,490		297,299
Total Assets		161,541,528		147,704,837

LIABILITIES

Current Liabilities

Distributions Payable (Note 11)		680,610		688,110
Accounts Payable and Accrued Liabilities (Note 8)		83,111		284,174
Total Liabilities (excluding Net Assets Attributable to Holders of Redeemable Units)		763,721		972,284
Net Assets Attributable to Holders of Redeemable Units	\$	160,777,807	\$	146,732,553
Redeemable Units Outstanding (Note 7)		13,612,199		13,737,199
Net Assets Attributable to Holders of Redeemable Units per Unit	\$	11.81	\$	10.68

The accompanying notes to financial statements are an integral part of these financial statements.

Approved by the Board of Directors of Middlefield Limited, as Manager:



Director: Jeremy Brasseur



Director: Craig Rogers

INTERIM FINANCIAL REPORT

UNAUDITED

Statements of Comprehensive Income

FOR THE SIX MONTHS ENDED JUNE 30

(In Canadian Dollars)

	2024	2023
REVENUE (LOSS)		
Income from Investments	\$ 1,876,609	\$ 1,059,974
Interest Income for Distribution Purposes	51,759	78,540
Foreign Exchange Gain (Loss) on Cash	13,566	73,350
Other Changes in Fair Value of Financial Assets and Financial Liabilities at Fair Value through Profit or Loss		
Net Realized Gain (Loss) from Investment Transactions excluding Derivatives	(381,046)	(595,134)
Net Realized Gain (Loss) from Derivatives Transactions	(708,880)	585,064
Change in Net Unrealized Gain (Loss) on Investments excluding Derivatives	20,091,935	(2,260,542)
Change in Net Unrealized Gain (Loss) on Derivatives Transactions	-	(118,920)
Change in Net Unrealized Gain (Loss) on Foreign Currency Transactions	22,341	138
Total Revenue (Loss)	20,966,284	(1,177,530)
OPERATING EXPENSES (Note 8)		
Audit Fees	20,277	12,136
Custodial Fees	12,033	6,929
Fund Administration Costs	96,713	128,116
Independent Review Committee Fees and Expenses	19,656	-
Legal Fees	20,621	7,569
Management Fee (Note 8)	810,530	494,319
Transaction Costs (Note 8)	67,990	56,352
Unitholder Reporting Costs	31,558	10,206
Total Operating Expenses	1,079,378	715,627
Withholding Taxes	188,004	156,469
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	\$ 19,698,902	\$ (2,049,626)
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit (Note 7)	\$ 1.43	\$ (0.21)

Statements of Changes in Net Assets Attributable to Holders of Redeemable Units

FOR THE SIX MONTHS ENDED JUNE 30

(In Canadian Dollars)

	2024	2023
Net Assets Attributable to Holders of Redeemable Units at Beginning of Period	\$ 146,732,553	\$ 88,625,742
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	19,698,902	(2,049,626)
Distributions to Unitholders	(4,137,410)	(3,036,174)
Payment on Redemption of Trust Units	(5,798,623)	(3,814,882)
Proceeds from Issue of Trust Units	4,282,385	81,147,960
Net Assets Attributable to Holders of Redeemable Units at End of Period	\$ 160,777,807	\$ 160,873,020

The accompanying notes to financial statements are an integral part of these financial statements.

INTERIM FINANCIAL REPORT

UNAUDITED

Statements of Cash Flows

FOR THE SIX MONTHS ENDED JUNE 30
(In Canadian Dollars)

	2024	2023
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES		
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	\$ 19,698,902	\$ (2,049,626)
Adjustments:		
Purchases of Investments	(74,165,219)	(116,466,041)
Proceeds from Sale of Investments	78,341,023	42,446,947
Foreign Exchange (Gain) Loss	(35,907)	(73,488)
Net Realized (Gain) Loss from Investment Transactions	1,089,926	10,070
Change in Net Unrealized (Gain) Loss on Investments	(20,091,935)	2,379,462
	4,836,790	(73,752,676)
Net Change in Non-Cash Working Capital	(82,254)	33,429
Net Cash from (used in) Operating Activities	4,754,536	(73,719,247)
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES		
Proceeds from Issue of Trust Units	4,282,385	81,147,960
Payment on Redemption of Trust Units	(5,798,623)	(3,814,882)
Distributions Paid to Unitholders	(4,144,910)	(2,688,990)
Net Cash from (used in) Financing Activities	(5,661,148)	74,644,088
Net Increase (Decrease) in Cash	(906,612)	924,841
Foreign Exchange Gain (Loss)	35,907	73,488
Cash at Beginning of Period	2,519,020	4,123,406
Cash at End of Period	\$ 1,648,315	\$ 5,121,735

The accompanying notes to financial statements are an integral part of these financial statements.

INTERIM FINANCIAL REPORT

UNAUDITED

Schedule of Investment Portfolio*

AS AT JUNE 30, 2024

(In Canadian Dollars)

Description	No. of Securities	Average Cost	Fair Value
Abbott Laboratories	27,000	\$ 3,665,961	\$ 3,838,987
AbbVie Inc.	35,000	5,943,866	8,214,447
Amgen Inc.	10,000	2,887,895	4,275,393
AstraZeneca PLC	43,000	6,418,567	9,190,113
Becton Dickinson and Co.	8,500	2,934,754	2,718,265
Boston Scientific Corp.	68,000	3,934,168	7,165,583
Danaher Corp.	11,500	2,615,946	3,931,631
DexCom, Inc.	25,000	3,350,497	3,878,573
DRI Healthcare Trust	175,000	1,975,535	2,756,250
Elevance Health Inc.	6,300	4,418,832	4,671,143
Eli Lilly & Company	10,400	3,781,654	12,884,268
Exact Sciences Corp.	25,000	1,561,830	1,445,314
Gilead Sciences Inc.	40,000	3,798,819	3,755,285
GSK PLC	110,000	2,804,305	2,910,159
Intuitive Surgical Inc.	8,000	2,192,200	4,869,665
Johnson & Johnson	31,354	6,492,633	6,270,714
Legend Biotech Corp.	11,000	644,439	666,644
McKesson Corp.	6,400	2,106,993	5,114,676
Medtronic PLC	30,000	3,552,472	3,231,072
Merck & Co., Inc.	50,000	6,152,811	8,470,054
Natera Inc.	12,000	1,335,261	1,778,137
Novartis AG	20,000	2,745,692	2,928,842
Novo Nordisk A/S	34,000	3,831,051	6,723,618
Pfizer Inc.	45,000	1,697,483	1,722,883
Regeneron Pharmaceuticals Inc.	1,600	2,052,366	2,301,074
Sanofi S.A.	32,000	4,262,545	4,220,801
Stryker Corp.	13,500	4,561,506	6,285,320
Thermo Fisher Scientific Inc.	8,500	3,951,629	6,431,904
UnitedHealth Group Inc.	12,000	6,125,308	8,362,119
Vertex Pharmaceuticals Inc.	6,000	1,725,070	3,848,223
Zoetis Inc.	10,000	2,114,823	2,372,162
HEALTHCARE: 91.3%		105,636,911	147,233,319
Chartwell Retirement Residences	570,000	5,148,864	7,324,500
Sienna Senior Living Inc.	165,000	2,283,152	2,351,250
Ventas Inc.	40,000	2,455,775	2,805,654
REAL ESTATE: 7.7%		9,887,791	12,481,404
TRANSACTION COSTS (Note 8)		(88,171)	-
TOTAL INVESTMENTS: 99.0%		115,436,531	159,714,723
CASH: 1.0%		1,648,315	1,648,315
Total Investment Portfolio, Including Cash		\$ 117,084,846	\$ 161,363,038

*22.7% of the Fund's net assets were held by Middlefield Income Plus Class, Middlefield Global Dividend Growers Class, MINT Income Fund, Middlefield Sustainable Global Dividend ETF and Middlefield U.S. Equity Dividend ETF (together the "Top Funds") as at June 30, 2024. Middlefield Limited acts as the manager for both the Fund and the Top Funds.

NOTES TO FINANCIAL STATEMENTS



NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

1. Middlefield Healthcare Dividend ETF

Middlefield Healthcare Dividend ETF (the “Fund”) is an exchange-traded fund established under the laws of the Province of Alberta on June 23, 2017. The Fund converted from a closed-end investment fund into an ETF on February 11, 2019. The Fund’s units were re-designated as units of the ETF on a 1:1 basis, and the Toronto Stock Exchange symbol changed from LS.UN to LS. The investment strategies of the Fund remain substantially similar before and after the conversion. On March 15, 2022, the name of the Fund was changed to Middlefield Healthcare Dividend ETF and the Toronto Stock Exchange symbol changed from LS to MHCD.

Middlefield Limited, a company incorporated in Alberta, is both the manager and trustee of the Fund (the “Manager”) and Middlefield Capital Corporation (“MCC”), a company under common control with the Manager, is the advisor to the Fund (the “Advisor”). The Fund was listed on the Toronto Stock Exchange and effectively commenced operations on July 21, 2017 when it first issued units through an initial public offering. The address of the Fund’s registered office is The Well, 8 Spadina Ave., Suite 3100, Toronto, Ontario. These financial statements, expressed in Canadian Dollars, were authorized for issuance by the board of directors of the Manager on August 23, 2024.

2. Investment Objectives and Strategy

The investment objectives of the Fund are to provide holders of units with: (i) stable monthly cash distributions; and (ii) enhanced long-term total return through capital appreciation of the Fund’s investment portfolio. The Fund utilizes an investment strategy which focuses primarily on investing in dividend-paying securities of issuers operating in or that derive a significant portion of their earnings or revenue from products or services related to the healthcare, life sciences and related industries.

3. Basis of Presentation

These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and in accordance with International Financial Reporting Standards 34 Interim Financial Reporting (“IAS 34”) as published by the International Accounting Standards Board (“IASB”) and as required by Canadian securities legislation and the Canadian Accounting Standards Board.

4. Summary of Material Accounting Policies

A. Basis of Accounting

IFRS 9 *Financial Instruments* (“IFRS 9”)

The Fund classifies and measures financial instruments in accordance with IFRS 9 which requires assets to be carried at amortized cost or fair value, with changes in fair value recognized in profit and loss or other comprehensive income, based on the entity’s business model for managing financial assets and the contractual cash flow characteristics of the financial assets. The Fund’s financial assets and liabilities are classified at fair value profit or loss (“FVTPL”) and amortized cost.

Classification, Measurement, Impairment and Hedge Accounting

The Fund classifies its investments in debt and equity securities based on its business model for managing those financial assets and the contractual cash flow characteristics of the financial assets. These financial assets are managed and their performance is evaluated on a fair value basis. The Fund also manages these financial assets with the objective of realizing cash flows through sales. Further, an option to irrevocably designate any equity securities at fair value through other comprehensive income (“FVOCI”) has not been taken. Consequently, these financial assets are mandatorily measured at FVTPL.

Financial assets or financial liabilities held for trading are those acquired principally for the purpose of selling or repurchasing in the near future or on initial recognition they are a part of a portfolio of identified financial instruments that the Fund manages together and has a recent actual pattern of short term profit taking. All derivatives and short positions are included in this category and mandatorily measured at FVTPL. The financial assets and liabilities measured at amortized cost include cash collateral posted on derivative positions, accrued income, due to and from brokers and other short term receivables and payables.

IFRS 9 uses the expected credit loss model (“ECL”), as the new impairment model for financial assets carried at amortized cost. The Fund’s financial assets measured at amortized cost consist of trade receivables with no financing component and which have maturities of less than 12 months, as such, it has chosen to apply the simplified ECL approach, whereby any loss allowance is recognized based on the lifetime of ECLs. Due to the high quality and short-term nature of the trade receivables, there are no expected credit losses associated with them and they are not considered impaired at the reporting dates.

The Fund does not apply general hedge accounting to any of its derivatives positions.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

4. Summary of Material Accounting Policies (continued)

B. Financial Instruments

The Fund's financial instruments may include: short-term investments, fixed income, equities, structured products including investment funds managed by the Manager, derivatives (collectively referred to as "investments"), cash, accounts receivable – portfolio securities sold, income and interest receivable, accounts receivable, subscriptions receivable, prepaid interest, prepaid expenses, loan payable, accounts payable – portfolio securities purchased, accounts payable and accrued liabilities, redemptions payable and distributions payable. The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments measured at amortized cost. Regular way purchases and sales of financial assets are recognized at their trade date. The Fund's investments and derivative assets and liabilities are measured at fair value. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid, discounted, when appropriate, at the contract's effective interest rate. The Fund's accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its net asset value ("NAV") for transactions with unitholders.

The Fund only offsets financial assets and financial liabilities if the Fund has a legally enforceable right to offset recognized amounts and either intends to settle on a net basis or to realize the asset and settle the liability simultaneously.

C. Fair Value Measurement

The Fund's own credit risk and the credit risk of the counterparty are taken into account in determining the fair value of financial assets and financial liabilities, including derivative instruments. Investments and futures contracts are valued at fair value using the policies described below.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets are based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances.

The fair value of financial assets and liabilities that are not traded in an active market (for example, over-the-counter derivatives) is determined by using valuation techniques. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each reporting date. Valuation techniques used include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants making the maximum use of market inputs and relying as little as possible on entity specific inputs.

D. Classification of Redeemable Units by the Fund

Under International Accounting Standard ("IAS") 32, *Financial Instruments: Presentation*, the Fund classifies its redeemable units as liabilities. The Fund's redeemable units do not meet the criteria in IAS 32 for classification as equity as the Fund has more than one contractual obligation to its unitholders.

E. Derivative Transactions

The Fund may use derivatives, such as forward currency contracts to hedge against losses caused by changes in exchange rates. The value of forward currency contracts is the gain or loss that would be realized, if on the valuation date, the positions were to be closed out. The change in value of forward currency contracts is included in the Statements of Comprehensive Income. Realized gains and losses from derivative instruments that are specific economic hedges are accounted for in the same manner as the underlying investments being hedged and are included in the Statements of Comprehensive Income.

F. Investment Transactions and Income Recognition

Investment transactions are accounted for as of the trade date and any realized gains or losses from such transactions are calculated on an average cost basis. Average cost does not include amortization of premiums or discounts on fixed income securities with the exception of zero coupon bonds. The change in the difference between fair value and average cost of the investments is recorded as unrealized gain (loss) on investments. Income from investments is recognized on the ex-dividend or ex-distribution date. Interest income for distribution purposes shown on the Statements of Comprehensive Income represents the interest from bank deposits received by the Fund and, if the Fund holds fixed income investments, coupon interest accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds which are amortized on a straight line basis. The interest income for distribution purposes is the tax basis of calculating the interest received and which is subject to tax. Income distributions received are treated consistently with dividends and interest and recorded in income in the Statements of Comprehensive Income.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

4. Summary of Material Accounting Policies (continued)

G. Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit

Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per unit in the Statements of Comprehensive Income represents the increase (decrease) in net assets divided by the average units outstanding during the period.

H. Taxation

The Fund qualifies as a mutual fund trust under the provisions of the *Income Tax Act (Canada)*. Under the terms of the Declaration of Trust, any taxable income of the Fund is distributable monthly to unitholders of record date. The Fund is not subject to tax on the income distributed to unitholders. Accordingly, no provision for income taxes is required.

The Fund currently incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown separately in the Statements of Comprehensive Income.

Distributions received from investments in trust units that are treated as a return of capital for tax purposes are used to reduce the average cost of the underlying investments on the Schedule of Investment Portfolio.

I. Foreign Currency Translation

Foreign currency amounts are translated into Canadian dollars as follows: fair value of investments, forward currency contracts and other assets and liabilities, at the closing rate of exchange on each business day; income and expenses, and purchases, sales and settlements of investments, at the rate of exchange prevailing on the respective dates of such transactions.

J. Critical Accounting Estimates and Judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

Determination of Functional Currency

'Functional currency' is the currency of the primary economic environment in which the Fund operates. If indicators of the primary economic environment are mixed, then management uses its judgment to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events and conditions. The majority of the Fund's investments and transactions are denominated in Canadian dollars. Investor subscriptions and redemptions are also received and paid in Canadian dollars. Accordingly, management has determined that the functional currency of the Fund is Canadian dollars.

Fair Value Measurement of Derivatives and Securities Not Quoted in an Active Market

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. Where no market data is available, the Fund may value positions using its own models, which are usually based on valuation methods and techniques generally recognized as standard within the industry. The models used to determine fair values are validated and periodically reviewed by experienced personnel of the Manager, independent of the party that created them. The models used for private equity securities are based mainly on earnings multiples adjusted for a lack of marketability as appropriate.

Models use observable data, to the extent practicable. However, areas such as credit risk (both own and counterparty), volatilities and correlations require the Manager to make estimates. Changes in assumptions about these factors could affect the reported fair values of financial instruments. The Fund considers observable data to be market data that is readily available, regularly distributed and updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. Refer to Note 5 for further information about the fair value measurement of the Fund's financial instruments.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

5. Fair Value Disclosure

The Fund classifies fair value measurements within a hierarchy which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The fair value of the Fund's financial instruments is classified into levels using the following fair value hierarchy:

Level 1	Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
Level 2	Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
Level 3	Inputs that are unobservable and where there is little, if any, market activity. Inputs into the determination of fair value require significant management judgment or estimation.

The Fund's investments at fair value as at June 30, 2024 and December 31, 2023 trade in active markets and are therefore classified as Level 1.

All fair value measurements are recurring. The carrying values of cash, income and interest receivable, subscriptions receivable, accounts receivable, prepaid interest, accounts receivable – portfolio securities sold, loan payable, distributions payable, and accounts payable and accrued liabilities, approximate their fair values due to their short-term nature. Fair values of Fund's investments in common shares are classified as Level 1 when the related security is actively traded and a quoted price is available. If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified into Level 2, unless the measurement of its fair value requires the use of significant unobservable inputs, in which case it is classified as Level 3.

No transfers between levels have occurred during the period ended June 30, 2024 or the year ended December 31, 2023.

6. Financial Risk Management

In the normal course of business, the Fund is exposed to a variety of financial risks: price risk, interest rate risk, liquidity risk, foreign exchange rate risk, credit risk and concentration risk. The Fund's primary risk management objective is to protect earnings and cash flow and, ultimately, unitholder value. Risk management strategies, as discussed below, are designed and implemented to ensure the Fund's risks and related exposures are consistent with its objectives and risk tolerance.

Most of the Fund's risks are derived from its investments. The value of the investments within the Fund's portfolio can fluctuate on a daily basis as a result of changes in interest rates, economic conditions, commodity prices, the market and company news related to specific securities held by the Fund. The investments are made in accordance with the Fund's risk management policies. The policies establish investment objectives, strategies, criteria and restrictions. The objectives of these policies are to identify and mitigate investment risk through a disciplined investment process and the appropriate structuring of each transaction.

A. Price Risk

Price risk is the risk that changes in the prices of the Fund's investments will affect the Fund's income or the value of its financial instruments. The Fund's price risk is driven primarily by volatility in commodity and equity prices. Rising commodity and equity prices may increase the price of an investment while declining commodity and equity prices may have the opposite effect. The Fund mitigates price risk by making investing decisions based upon various factors, including comprehensive fundamental analysis prepared by industry experts to forecast future commodity and equity price movements. The Fund's market positions are monitored on a daily basis by the portfolio manager and regular financial reviews of publicly available information related to the Fund's investments are performed to ensure that any risks are within established levels of risk tolerance. The Fund is exposed to price risk through the following financial instrument:

	June 30, 2024	December 31, 2023
Investments at FVTPL	\$ 159,714,723	\$ 144,888,518

Based on the above exposure at June 30, 2024, a 10% increase or decrease in the prices of the Fund's investments would result in a \$15,971,472 (December 31, 2023 - \$14,488,852) increase or decrease in net assets of the Fund, with all other factors held constant.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

6. Financial Risk Management (continued)

B. Interest Rate Risk

Interest rate risk describes the Fund's exposure to changes in the general level of interest rates. Interest rate risk arises when the Fund invests in interest-bearing financial assets such as cash and utilizes financial liabilities such as loan payable. In respect of cash balances and loan payable, the Fund's interest income and expense are positively correlated to interest rates in that rising interest rates increase both interest income and expense while the reverse is true in a declining interest rate environment. The Fund has not hedged its exposure to interest rate movements. The Fund seeks to mitigate this risk through active management, which involves analysis of economic indicators to forecast Canadian and global interest rates. The Fund is exposed to interest rate risk through the following financial instrument:

	June 30, 2024	December 31, 2023
Cash	\$ 1,648,315	\$ 2,519,020

Based on the above exposure at June 30, 2024, a 1% per annum increase or decrease in interest rates would result in a \$16,483 (December 31, 2023 - \$25,190) increase or decrease in net assets of the Fund, with all other factors held constant.

C. Liquidity Risk

Liquidity risk is defined as the risk that the Fund may not be able to settle or meet its obligations when due. The Fund is subject to the potential daily net redemptions of units. Liquidity risk is managed by investing the majority of the Fund's assets in investments that are traded in an active market and can be readily sold. The Fund retains sufficient cash to maintain liquidity and comply with liquidity requirements as outlined by securities legislation and its investment policies.

The Fund may invest in securities that are not traded on public stock exchange or that may be illiquid. As a result, the Fund may not be able to dispose of these investments in a timely manner. The Fund mitigates this risk through active management, which includes detailed analysis of such entities to ensure they are financially sound and would be attractive to potential investors if a sale is necessary. The Fund's investment policies and securities legislation limit the amount invested in illiquid securities and these limits are monitored. At June 30, 2024 or December 31, 2023, the Fund did not hold any illiquid securities.

The tables below present the Fund's financial liabilities based on the remaining period to the contractual maturity date. The amounts in the tables reflect the contractual undiscounted cash flows.

As at June 30, 2024

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Distributions Payable	\$ 680,610	\$ -	\$ -	\$ 680,610
Accounts Payable and Accrued Liabilities	83,111	-	-	83,111
Net Assets Attributable to Holders of Redeemable Units	160,777,807	-	-	160,777,807
Total	\$ 161,541,528	\$ -	\$ -	\$ 161,541,528

As at December 31, 2023

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Distributions Payable	\$ 688,110	\$ -	\$ -	\$ 688,110
Accounts Payable and Accrued Liabilities	284,174	-	-	284,174
Net Assets Attributable to Holders of Redeemable Units	146,732,553	-	-	146,732,553
Total	\$ 147,704,837	\$ -	\$ -	\$ 147,704,837

The Manager does not expect that the contractual maturity disclosed above will be representative of the actual cash outflows, as holders of these instruments typically retain them for a longer period.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

6. Financial Risk Management (continued)

D. Foreign Exchange Rate Risk

Foreign exchange rate risk describes the impact on the underlying value of financial instruments due to foreign exchange rate movements. The Canadian dollar is the Fund's functional and reporting currency. Foreign investments, commodities, cash, receivables and payables denominated in foreign currencies are affected by changes in the value of the Canadian dollar compared to foreign currencies. As a result, financial assets may depreciate/appreciate in the short-term due to the strengthening/weakening of the Canadian dollar against other currencies, and the reverse would be true for financial liabilities. The Fund's exposure to foreign exchange rate risk relates primarily to its investment in securities, which are denominated in various foreign currencies. The Fund has not hedged its exposure to currency fluctuations; however, it closely monitors relevant foreign exchange currency movements. The Fund is exposed to foreign exchange rate risk through the following financial instruments denominated in various foreign currencies:

As at June 30, 2024

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	\$ 121,309,191	\$ 1,360,792	\$ 113,198	\$ 122,783,181
U.K. Pound Sterling	12,100,272	-	23,351	12,123,623
Danish Krone	6,723,617	-	-	6,723,617
European Euro	4,220,801	-	-	4,220,801
Swiss Franc	2,928,842	-	-	2,928,842
Total	\$ 147,282,723	\$ 1,360,792	\$ 136,549	\$ 148,780,064

As at December 31, 2023

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	\$ 110,634,069	\$ 1,418,543	\$ 191,285	\$ 112,243,897
U.K. Pound Sterling	10,683,989	-	16,473	10,700,462
Danish Krone	4,637,804	-	-	4,637,804
European Euro	4,183,823	-	-	4,183,823
Swiss Franc	2,681,383	-	-	2,681,383
Total	\$ 132,821,068	\$ 1,418,543	\$ 207,758	\$ 134,447,369

Based on the above exposure at June 30, 2024, a 10% increase or decrease in the Canadian dollar against the respective foreign currencies would result in a \$14,878,006 (December 31, 2023 - \$13,444,737) decrease or increase in net assets of the Fund, with all other factors held constant.

E. Credit Risk

Credit risk represents the financial loss that the Fund would experience if a counterparty to a financial asset failed to meet its obligations to the Fund. The Fund is exposed to credit risk on its debt instruments, derivative assets, cash and cash equivalents and other short term trade receivables. The Fund measures credit risk and lifetime ECLs related to the trade receivables using historical analysis and forward looking information in determining the ECL. The carrying amounts of financial assets represent the maximum credit exposure. All transactions executed by the Fund in listed securities are settled upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase only once the broker has received the securities. The trade will fail if either party fails to meet its obligations. There is no significant credit risk related to the Fund's receivables.

The Fund has established various internal controls to help mitigate credit risk, including prior approval of all investments by the Advisor whose mandate includes conducting financial and other assessments of these investments on a regular basis. The Fund has also implemented policies which ensure that investments can only be made with counterparties that have a minimum acceptable credit rating.

F. Concentration Risk

The Fund is exposed to the possible risk inherent in the concentration of the investment portfolio in a small number of industries or investment sectors. The Manager moderates this risk through careful selection of securities in several investment sectors. At June 30, 2024 and December 31, 2023, the percentages of the Fund's net assets invested in each investment sector were as follows:

Sector	As a % of Net Assets	
	June 30, 2024	December 31, 2023
Healthcare	91.5	92.0
Real Estate	7.8	6.7
Total	99.3	98.7

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

7. Redeemable Units

Authorized

The Fund is authorized to issue an unlimited number of transferable, redeemable units, each of which represents an equal, undivided interest in the net assets of the Fund. All units have equal rights and privileges. Unitholders may sell units on the TSX; in addition, unitholders may: (a) redeem units of the Fund for cash at a redemption price per unit equal to the lesser of: (i) 95% of the closing price for the applicable units on the TSX; and (ii) the net asset value per unit, on the effective day of redemption less any costs associated with the redemption; or (b) exchange a prescribed number of units (PNU) or a multiple PNU of the fund for Baskets of Securities and/or cash at an exchange price equal to the net asset value of that number of units less any costs associated with the redemption as determined by the Manager in its sole discretion. Unitholders of the Fund can acquire additional units by participating in the Distribution Reinvestment Plan (the "Plan"). The Plan enables unitholders to reinvest their monthly distributions in additional units of the Fund thereby achieving the benefit of compounding returns. The Plan also allows participants to purchase additional units for cash.

On July 21, 2017, the Fund issued 10.2 million units at \$10.00 per unit for proceeds, net of agents' fees and issue costs, of \$96.6 million. On August 18, 2017, the Fund issued 120,000 units at \$10.00 per unit for proceeds, net of agents' fees, of \$1.1 million. On May 17, 2023, the Fund issued 6,393,678 units in exchange for units of merged Sustainable Agriculture & Wellness Dividend Fund and Middlefield Health & Wellness ETF. During the period ended June 30, 2024, the Fund redeemed 500,000 units (June 30, 2023 – 350,000) and issued 375,000 units (June 30, 2023 – 900,000). For the period ended June 30, 2024, 3,575 units (June 30, 2023 – 2,839) were distributed under the Plan.

The average number of units outstanding during the period ended June 30, 2024 was 13,813,710 (June 30, 2023 – 9,589,623). This number was used to calculate the Net Assets Attributable to Holders of Redeemable Units per unit.

8. Related Party Transactions

A. Management Fee

The Manager provides investment and administrative services to the Fund. In consideration for such services, the Manager receives a management fee equal to 0.85% per annum of the NAV, calculated and paid monthly in arrears based on the average NAV of the preceding month. For the period ended June 30, 2024, management fees before the absorption of expenses amounted to \$0.7 million (June 30, 2023 - \$0.4 million). At June 30, 2024, the management fees payable by the Fund was \$104,413 (December 31, 2023 - \$98,805) and is included in Accounts Payable and Accrued Liabilities.

B. Transaction Costs

Brokerage commissions and other transaction costs paid in connection with securities transactions during the period ended June 30, 2024 amounted \$67,990 (June 30, 2023 - \$56,352). Included in this amount is \$2,707 (June 30, 2023 - \$12,152) in brokerage commissions that were paid to MCC. All commissions paid by the Fund to MCC were at or below market rates. Brokerage commissions and other transaction costs are expensed and recorded in the Statements of Comprehensive Income.

C. Other Expenses

The Fund is responsible for the payment of all expenses relating to the operation of the Fund and the carrying on of its business, including, among other things, audit and legal fees and expenses, custodian and transfer agency fees, and costs relating to securityholder reporting. Certain services in the normal course of business may be provided by the Manager or an affiliate of the Manager in accordance with National Instrument 81-107 – *Independent Review Committee for Investment Funds*. Examples of these services include the preparation and filing of tax returns, the preparation and filing of financial statements and related reports, acting as transfer agent and registrar for the funds, and maintaining and updating the Fund's website. In aggregate, these fees amounted \$44,689 (June 30, 2023 - \$30,652) throughout the period and \$13,966 (December 31, 2023 - \$6,600) is included in Accounts Payable and Accrued Liabilities as at June 30, 2024. In addition, the Fund would be responsible for reimbursing the Manager for any reasonable out of pocket expenses incurred on the Fund's behalf.

9. Capital Management

The Fund's capital is its net assets attributable to holders of redeemable units. The Fund's objective when managing capital is to safeguard the Fund's ability to continue as a going concern in order to provide returns for unitholders, maximize unitholder value and maintain financial strength. The Fund manages and adjusts its capital in response to general economic conditions, the risk characteristics of the underlying assets and working capital requirements.

The Fund is not subject to any externally imposed capital requirements. The Fund's overall strategy with respect to capital risk management remains unchanged from the year ended December 31, 2023.

10. Loss Carryforwards

At December 31, 2023, the Fund had capital losses of \$115,810 (December 31, 2022 - \$nil) and no non-capital losses (December 31, 2022 - \$1,547,144) available for carryforward for tax purposes.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2024 | UNAUDITED

11. Distributions

The Fund pays monthly distributions to unitholders in accordance with its investment objectives. Effective December 29, 2017, distributions of the Fund, at the discretion of the unitholder, are reinvested in additional units of the Fund under the Distribution Reinvestment Plan, without sales charge. For the six months ended June 30, 2024, distributions amounted to \$0.30 per unit (June 30, 2023 – \$ 0.30).

Other investment funds managed by the Manager have invested in the Fund. The distributions payable to those investment funds amounted to \$154,400 as at June 30, 2024 (December 31, 2023 - \$139,287) and was included in the amount of Distribution Payable shown on the Statements of Financial Position.

Dean Orrico

President and Chief Executive Officer

Jeremy T. Brasseur

Executive Chairman

Robert F. Lauzon, CFA

Chief Investment Officer

Independent Review Committee**H. Roger Garland, CPA, CA**Former Vice-Chairman
Four Seasons Hotels Inc.**Christine Helsdon Tekker, MBA, LLM, ICD.D**Senior Vice President, Lending
Infrastructure Ontario**Edward V. Jackson (Chairman)**Former Managing Director
RBC Capital Markets**Advisors**Middlefield Capital Corporation
SSR Health LLC
Paul Sagawa LLC**Middlefield Group****Stephen Erlichman**Chair, ESG
(Environmental, Social, Governance)**Craig Rogers, CPA, CGA, CFA**

Chief Operating Officer

Wendy Teo, CPA, CA, CPA (IL)

Chief Financial Officer & Vice President

Mark Aboud

Chief Experience Officer

Dennis da Silva

Senior Portfolio Manager

Nancy Tham

Managing Director, Sales

Shane Obata

Portfolio Manager

Robert Moffat

Portfolio Manager

Anthony Tavella, MBA, MFin

Executive Director, International and Marketing

Stacy J. Crestohl

Director, Operations

Rose Espinoza

Director, International

Catherine Rebuldela, CPA, CGA

Director, Operations

Victor Xu, CFA

Director, Corporate Development

Shiranee Gomez

Senior Vice-President

Victor Ngai

Senior Vice-President

Nicole S. Brasseur

President, Human Resources

Sarah Roberts, CPA, CMA

Vice-President

Jimmy Xu

Vice-President, Information Technology

Rachel Zhang

Vice-President

Sylvia Casillano, CPA, CGA

Assistant Vice-President

Maggie Vanadero – Chu

Assistant Fund Admin

Morgan Byrne

Director, Sales

Scott Hu

Associate, Information Technology

AJ Mamatalieva

Business Development Manager, Sales

Mazhar Ahsan Abdulwahab

Investment Analyst

Celynn Kuros

Business Development Associate, Sales

Curtis Blakely

Business Development Associate

Juanita Lam

Brand Designer

Joshua Wiggins

Brand Strategist

AuditorDeloitte LLP, Chartered Professional Accountants
RSM Canada LLP**Legal Counsel**DLA Piper (Canada) LLP
Fasken Martineau DuMoulin LLP
McCarthy Tétrault**Bankers**Bank of Montreal
Canadian Imperial Bank of Commerce
Royal Bank of Canada
The Bank of Nova Scotia
The Toronto-Dominion Bank**Custodian**

RBC Investor Treasury Services

Transfer AgentsRBC Investor Service Trust
TSX Trust Company**Affiliates**Middlefield Group Limited
Middlefield Capital Corporation
Middlefield Financial Services Limited
MFL Management Limited
MF Properties Limited
Middlefield International Limited
Middlefield Limited
Middlefield Realty Services Limited
Middlefield Resource Corporation

MIDDLEFIELD FUNDS FAMILY |

EXCHANGE - TRADED FUNDS (ETFs)	TSX Stock Symbol
• Middlefield Healthcare Dividend ETF	MHCD
• Middlefield Innovation Dividend ETF	MINN
• Middlefield Sustainable Global Dividend ETF	MDIV
• Middlefield Sustainable Infrastructure Dividend ETF	MINF
• Middlefield Real Estate Dividend ETF	MREL
• Middlefield U.S. Equity Dividend ETF	MUSA
TSX-LISTED FUNDS	
• E Split Corp.	ENS ENS.PR.A
• Middlefield Global Real Asset Fund	RA.UN
• MINT Income Fund	MID.UN
• Real Estate Split Corp.	RS RS.PR.A
• Sustainable Innovation & Health Dividend Fund	SIH.UN
• Infrastructure Dividend Split Corp. (commenced May 8, 2024)	IS IS.PR.A
MIDDLEFIELD MUTUAL FUNDS TRUST FUNDS	
Series A Units	Fund Code FE/LL/DSC
• Middlefield Healthcare Dividend Fund	MID 325/327/330
• INDEXPLUS Income Fund	MID 435/437/440
• Middlefield Global Infrastructure Fund	MID 510/519/520
Series F Units	
• Middlefield Healthcare Dividend Fund	MID 326
• INDEXPLUS Income Fund	MID 436
• Middlefield Global Infrastructure Fund	MID 501
MIDDLEFIELD MUTUAL FUNDS CORPORATE CLASS FUNDS	
Series A Shares	Fund Code FE/LL/DSC
• Middlefield Canadian Dividend Growers Class	MID 148/449/450
• Middlefield Global Agriculture Class	MID 161/163/166
• Middlefield Global Dividend Growers Class	MID 181/183/186
• Middlefield Real Estate Dividend Class	MID 600/649/650
• Middlefield ActivEnergy Dividend Class (formerly, Middlefield Global Energy Transition Class)	MID 265
• Middlefield Innovation Dividend Class	MID 925
• Middlefield High Interest Income Class	MID 400/424/425
• Middlefield Income Plus Class	MID 800/849/850
• Middlefield U.S. Equity Dividend Class	MID 710/719/720
Series F Shares	
• Middlefield Canadian Dividend Growers Class	MID 149
• Middlefield Global Agriculture Class	MID 162
• Middlefield Global Dividend Growers Class	MID 182
• Middlefield Real Estate Dividend Class	MID 601
• Middlefield ActivEnergy Dividend Class (formerly, Middlefield Global Energy Transition Class)	MID 266
• Middlefield Innovation Dividend Class	MID 926
• Middlefield Income Plus Class	MID 801
• Middlefield U.S. Equity Dividend Class	MID 701
RESOURCE FUNDS	
• Discovery 2023 Short Duration LP	
• MRF 2023 Resource Limited Partnership	
• MRF 2024 Resource Limited Partnership (commenced February 22, 2024)	
INTERNATIONAL FUNDS	
• Middlefield Canadian Income PCC	London UK Stock Exchange (LSE) Symbol:MCT



MIDDLEFIELD

INVESTMENTS THAT WORK FOR YOU

TORONTO, CANADA

The Well
8 Spadina Avenue, Suite 3100
Toronto, Ontario
Canada M5V 0S8
Telephone (416) 362-0714

LONDON, ENGLAND

Middlefield International Limited
288 Bishopsgate London,
England EC2M 4QP
Telephone (0207) 814-6644
Fax (0207) 814-6611

www.middlefield.com
invest@middlefield.com
(888) 890-1868